1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Can RFID Tags Give Generics Companies An Edge?

Fresenius Kabi Adds Radio Frequency-Identification Tags To 24 Products

 
• By Ben Comer

Fresenius Kabi’s decision to add radio frequency-identification (RFID) tags to 24 products used in hospital operating rooms will help the company’s hospital pharmacy customers reduce waste, increase efficiencies and facilitate tighter medication inventory control, executives claim. However, only 10% of US hospitals are currently equipped to scan and process RFID tags, despite larger adoption rates in other industry sectors. COVID-19-related revenue losses may push more hospitals to adopt automated RFID medication management systems to save time and reduce labor costs.

Radio frequency identification technology isometric vector concept with RFID reader or scanner, electromagnetic track tag on cardboard box, mobile app for business delivery, goods shipment tracking
RFID Tags Could Give Generics Companies An Edge • Source: Shutterstock

US hospitals and health systems are a critical customer segment for biopharma companies. But the costs of purchasing specialty products, such as orphan drugs and immunosuppressants, as well as drug shortages and price increases among certain generic products – prior to the COVID-19 pandemic – led one in four hospitals to cut staff between 2015 and 2017, according to a 2019 American Hospital Association (AHA) survey. In 2020, COVID-19 created new havoc on hospital and health system budgets; during the four-month period between March 1 and June 30, American hospitals and health systems lost a total of $202.6bn in revenues, or over $50bn per month, according the AHA. Like many business sectors, hospitals, with decreases in elective procedures and new spending on personal protective equipment, are feeling the pinch.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

More from Business

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

Roche Suggests Perjeta Biosimilars May Not Hit Until 2027 ‘Or Later’

 
• By Dean Rudge

Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.